 NASH was once the next big thing for big pharma; a newly defined disorder requiring chronic treatment afflicting millions of people in developed countries. In May, a French company called GNFTticker: GNFT, which had one of the most advanced NASH programs, announced that a Phase 3 trial of its NASH drug Elafinbranor had failed to achieve its primary endpoint. Now, another setback is tanking shares of ICPTICPT, which analysts had expected to introduce the first NASH drug sometime this year. 